Dr. Fischer is a co-founder of Quadriga BioSciences, Inc. and serves as Quadriga’s VP of Biology. For more than 25 years, Dr. Fischer focused his research on the SAR of membrane transporters of various different species. Dr. Fischer’s expertise ranges from bench scientist to technical entrepreneur. Before co-founding Quadriga BioSciences, Dr. Fischer was a distinguished Principal Investigator at XenoPort, a leader in the design of actively transported pro-drugs. During his tenure at XenoPort from 2001-2010, Dr. Fischer and his team determined the SAR of numerous transporters, which established the foundation of XenoPort's Transported Prodrugs™ technology platform. He and his team worked on various R&D programs, ranging from metabolic diseases, to infectious diseases and CNS syndromes, including schizophrenia, depression and alcoholism. From 1999 to 2001, Dr. Fischer headed the Plant Nutrition at Paradigm Genetics, Inc., a Genomics based company located in Research Triangle Park. The focus of his group was to maximize product quality and yield by optimizing nutrient acquisition and distribution within plants via modified membrane transporter expression. Prior to Paradigm Genetics, Dr. Fischer held various positions at the Max-Planck Institute for Molecular Genetics (Institut für Genbiologische Forschung, Berlin Germany), Eberhard-Karls University (Tübingen, Germany) and UCLA School of Medicine (Los Angeles, Califronia). Dr. Fischer received his Ph.D. in Biology form the University of Eberhard Karls University Tübingen (Germany) and his M.S. in Chemistry from the Technical University Berlin (TU-Berlin, Germany).
Dr. Jandeleit is a co-founder of Quadriga BioSciences, Inc. and serves as Quadriga’s VP of Chemistry since conception of the company in late 2010. Dr. Jandeleit’s career spans more then 20 years in the biopharmaceutical and life sciences industries. From 2000 to 2010, he worked at XenoPort, Inc., a company engaged in improving the clinical utility of medicines by exploiting active transport mechanisms to optimize pharmacokinetic properties of drugs. As an Associate Director, he was as a project leader for multiple R&D programs in a variety of therapeutic areas. He was also essential in profiling prevalence and specificity of solute carrier nutrient transporters for drug delivery for XenoPort's Transported Prodrugs™ technology platform. From 1997 to 2000, he served as a Sr. Staff Scientist and Lead Organic Chemist at Symyx Technologies, Inc. (now Accelerys, Inc.), a pioneer in combinatorial and high-throughput R&D approaches toward catalysis and materials science. As a fellow of the German National Scholarship Foundation and BASF AG, he conducted postdoctoral research from 1995 to 1997 in the labs of Prof. K.C. Nicolaou at The Scripps Research Institute, La Jolla. Dr. Jandeleit received his MS and PhD degrees, both with summa cum laude, from the RWTH Aachen University in Germany with Prof. D. Enders. He was awarded the prestigious Borcher's Batch and the Springorum Medal. He is an inventor on almost 30 granted national and international patents, numerous pending US and PCT patent applications, and a co-author on over 30 publications in peer-reviewed journals. Several of his molecules were licensed to pharmaceutical companies including tranexamic acid prodrug XP21510 that was licensed for an aggregate of $147M.
Kerry is one of our founders and the Vice President of Molecular Pharmacology. She has nearly 30 years experience working in biotechnology, focusing primarily on transporter and receptor biology. Her discovery and development expertise includes target ID, assay development, candidate selection, and IND-enabling studies.
Prior to Quadriga, Kerry held positions of increasing responsibility at Genentech, Affymax, and XenoPort, where she was most recently Senior Director of Discovery Biology. Kerry graduated with a B.S. in Chemistry, Honors, from Stanford University. She received her Ph.D. in Biochemistry/Neuropharmacology at the Johns Hopkins University School of Medicine. She is an author and inventor on over 40 scientific papers and patents.